CN1078472C - Application of theachrome in preparing medicine for plateau erythrocytosis - Google Patents
Application of theachrome in preparing medicine for plateau erythrocytosis Download PDFInfo
- Publication number
- CN1078472C CN1078472C CN97116635A CN97116635A CN1078472C CN 1078472 C CN1078472 C CN 1078472C CN 97116635 A CN97116635 A CN 97116635A CN 97116635 A CN97116635 A CN 97116635A CN 1078472 C CN1078472 C CN 1078472C
- Authority
- CN
- China
- Prior art keywords
- tea pigment
- plateau
- medicine
- erythrocytosis
- high altitude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000008601 Polycythemia Diseases 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims description 28
- 239000000049 pigment Substances 0.000 claims abstract description 51
- 241001122767 Theaceae Species 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000013616 tea Nutrition 0.000 description 47
- 244000269722 Thea sinensis Species 0.000 description 36
- 230000000694 effects Effects 0.000 description 19
- 210000003743 erythrocyte Anatomy 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 5
- 238000004820 blood count Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000282 nail Anatomy 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000014620 theaflavin Nutrition 0.000 description 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 2
- 229940026509 theaflavin Drugs 0.000 description 2
- 235000008118 thearubigins Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001170115 Rhodiola kirilowii Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000003948 acquired polycythemia Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 208000013213 secondary polycythemia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a new medicinal use of tea pigment, namely that the tea pigment can be used for curing plateau erythrocythemia.
Description
The present invention relates to the new medicine use of tea pigment, be specifically related to the application of tea pigment in the medicine of preparation high altitude erythrocytosis, belong to the field of Chinese medicines.
Tea pigment is the natural plant pigment that extracts from Folium Camelliae sinensis, is a kind of active pigment complex that catechin forms through peroxidating in the tea polyphenols.Tea pigment is made up of theaflavin, thearubigins and abrownin.For the existing bibliographical information of the research of tea pigment.CN1074618A discloses tea pigment and production method thereof.This production process is, Folium Camelliae sinensis is through decocting extracting juice, and alkalization concentrates, and acidify adds alcohol reflux, and alcohol reflux liquid alkalizes and obtains tea pigment crystallization product, through vacuum drying, promptly obtains this tea pigment.Theaflavin, thearubigins and abrownin three have constant ratio in the tea pigment that makes with this method, can be used as medicinal.Medical value report for tea pigment may be summarized to be reduction blood viscosity, blood fat reducing, cholesterol reducing, prevention and treatment cardiovascular disease.But up to the present, the relevant tea pigment of Shang Weijian is used for the treatment of the report of plateau cytosis.The direct murderous case of high altitude erythrocytosis is few, but can make large quantities of builder's forfeitures or reduce work capacity such as aid Tibet.Current main treatment measure is to withdraw the plateau, reduces labor intensity or slowly acclimatization and adaptation.Present oral Chinese medicine and western medicine medicine still can not prevent and control the outbreak of high red disease, and composite treatment comprises Hyperbaric oxygen chamber, quantum tachometer etc., though curative effect reaches 88.3%, is mostly to enter the result of low altitude area treatment.Seeking on-site treatment and the oral drugs of preventive effect are arranged is plateau medicine worker pursuits for many years.
The object of the invention provides a kind of new pharmaceutical applications of tea pigment, i.e. the application of tea pigment in the medicine of preparation treatment high altitude erythrocytosis.
High altitude erythrocytosis is common a kind of chronic high altitude disease.Oxygen-derived free radicals is apparently higher than healthy people in this disease patient blood, and superoxide dismutase is starkly lower than healthy people, causes oxygen-derived free radicals to be accumulated for a long time in vivo, causes the infringement of histoorgan and function.Tea pigment treatment high altitude erythrocytosis of the present invention has good curative effect.
The extracting method of tea pigment of the present invention can extract according to known extraction process, preferably the tea pigment that extracts according to following method:
(1), with Folium Camelliae sinensis by 1: after 15-30 multiple proportions example added water, through once or the decoction extracting juice once, fried liquid is used in the aqueous solution can produce OH
-Ionic chemical compound alkalizes, and regulates PH8-10, at the 1/4-1/10 that heats concentrated this alkaline solution to the original volume amount down less than 70 ℃, gets concentrated solution then; (2) concentrated solution transfers to PH3-6 with acid, and acidifying solution adds ethanol 1-10 volume doubly to be measured, and backflow 0.5-2 hour, gets alcohol reflux liquid; (3) alcohol reflux liquid is used in the aqueous solution and can produces OH
-Ionic chemical compound is regulated PH7-10, and post precipitation filters, and gets the tea pigment crystallization, and the tea pigment crystallization promptly gets the tea pigment product through vacuum drying.
Tea pigment of the present invention is a kind of active constituents of medicine, preparation process according to routine, can be main active constituent with tea pigment, add excipient substances such as conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, make any dosage form that is suitable for using clinically, as tablet, capsule, granule, oral liquid, injection etc.
Because the present invention discloses the pharmacologic action of tea pigment treatment high altitude erythrocytosis first; therefore; tea pigment cooperated separately or with other active constituents or adjuvant make medicament,, all belong to protection scope of the present invention so long as this medicament is used for the treatment of high altitude erythrocytosis.
Tea pigment of the present invention all has the effect of treatment high altitude erythrocytosis when making any dosage form.Any medicament; if contain tea pigment in its tissue or only prepare patent medicine with the tea pigment single component; on signs such as its packing or description or on other any propaganda materials, need only effect dated or that prompting has the treatment high altitude erythrocytosis, then fall within protection scope of the present invention.
Tea pigment of the present invention is the natural plants Folium Camelliae sinensis that derives from medicine-food two-purpose.Therefore, also tea pigment can be made health food or health care medicine.Health food or health care medicine with tea pigment is made have the effect for the treatment of high altitude erythrocytosis if indicate or point out on signs such as its packing or description, also fall within protection scope of the present invention.
Embodiment 1
Prescription
Tea pigment 125 grams
Medical starch 875 grams
Above-mentioned component is gone into blender, and fully stirring and evenly mixing is encapsulated with capsule machine, and every filling 1 gram makes 1000 of tea pigment capsules, and every capsules contains 125 milligrams of tea pigments.
Embodiment 2
Tea pigment 250 grams
2000 milligrams of distilled water
Stevioside 1 gram
Tea pigment is dissolved in the distilled water, and fully mixing adds stevioside, and stirring and evenly mixing is once more packed in the vial with can packing machine, and every bottled 10 milliliters, sterilization makes the tea pigment oral liquid.
Experimental example 1 tea pigment capsule is to the observation of curative effect of high altitude erythrocytosis
1, data
1.1 area: location, mansion, Golog state, Qinghai Province (3,719m), atmospheric pressure 63.98kpa, aerial oxygen dividing potential drop 7.28kpa.
1.2 object: officers and men People's Armed Police of the army of state in the Golog and family members 50 routine high altitude erythrocytosis patients, male's 42 examples wherein, women's 8 examples: the age, between year, the mean age was 29 years old at 9-53.The diagnostic criteria of 50 routine high altitude erythrocytosiss meets professor Wu Tianyi and waits " erythrocyte＞6.5 * 10 in the proposition blood parameters
12/ L, hemoglobin＞200g/L, packed cell volume＞0.651/L " standard.And got rid of the illness of the secondary polycythemia that chronic bronchitis, chronic cardiopulmonary disease, polycythemia vera, congenital heart disease etc. cause on inspection.
1.3 medicament sources: tea pigment capsule is provided by the green pharmaceutical Co. Ltd in Jiangxi; Authentication code: the accurate word of medicine (94) 139-1 number defended in Jiangxi, product batch number: 940804, and every of specification contains tea pigment 125mg.Usage: 125mg, every day 3 times, be a course of treatment February.Medication period is withdrawn relevant other medicines.
2, methods of clinical observation:
2.1 observation item: hematochrome, red blood cell count(RBC) and three indexs of packed cell volume.
2.2 observational technique: measure hematochrome, erythrocyte, packed cell volume before experimenter's oral drugs, measuring process is finished by same position doctor.
2.3 efficacy assessment standard: produce effects: patient's hematochrome drops to 142-159g/L, red blood cell count(RBC) drops to 4.5-5.2 * 10
12/ L, packed cell volume are reduced to 0.45-0.52L/L.Effectively: patient's hematochrome is reduced to 160g-180g/L, red blood cell count(RBC) is reduced to 5.2-6.0 * 10
12/ L, packed cell volume are reduced to 0.52-0.6L/L.Invalid: as though patient's blood bag is plain decline is arranged, but still more than 200g/L, red blood cell count(RBC) to be in 6.0-6.6 * 10
12/ L, packed cell volume is more than 0.65L/L.Produce effects 22 examples account for 44%; Effective 26 examples account for 52%, and invalid 2 examples account for 4%, and total effective rate is 96%.
3, result
The results are shown in following table
Physiochemical indice changed before and after tea pigment capsule was taken medicine to 50 routine high altitude erythrocytosis patients:
| Test item | Before the treatment | After the treatment | The t value |
| Hb(g/L) | 218±38.4 | 164±36.86 | 1.872 |
| Rbc(×10 12/L) | 6.85±0.75 | 5.1±0.68 | 2.871 |
| HCT(L/L) | 0.678±0.086 | 0.525±0.075 | 2.872 |
Annotate: with preceding relatively P＜0.05 of treatment
Discuss:
1, high altitude erythrocytosis is common a kind of chronic high altitude disease.Environment of low oxygen plateau is regarded as influencing the main cause that the person healthy and some people in plateau suffers from high altitude erythrocytosis.Also there is the scholar to propose to be because of some people who lives in the plateau because of hypoxia stress, causes that a kind of pathologic that hemopoietic function or its regulatory mechanism get muddled changes.It is because hypoxia increases kidney erythropoitinogen enzyme secretion, and erythropoietin increases, and the latter makes the hemocytoblast in the bone marrow also promote later on further hypertrophy and maturation.In recent years discover, oxygen-derived free radicals is apparently higher than healthy people in high altitude erythrocytosis patient's blood, and the superoxide dismutase of removing oxygen-derived free radicals is starkly lower than healthy people, causes oxygen-derived free radicals to be accumulated for a long time in human body, causes the infringement of histoorgan and function.
2, tea pigment is a green tea extract, has the blood fat of improvement, anticoagulant, molten fibre, removes free radical, improves vascular endothelial function, can prevent and treat aspect diseases such as many hearts, cerebrovascular.We use tea pigment capsule 50 routine high altitude erythrocytosiss are carried out clinical observation, and the result has obtained good curative effect.Hb, Rbc, Hct significantly descend (P＜0.05) before than treatment, reduce to not see in normal range and continue to descend, and the mental status, appetite, physical strength, memory obviously improve.The author thinks that this medicine can improve the utilization of body to blood oxygen, has anti-hypoxia, the scarce O of enhancing body tolerance
2Ability; Can regulate the physiological process of body hemopoietic function disorder, make it to transform towards normally helping the body aspect.With the removing oxygen-derived free radicals, reduce it and in body, accumulate, damage relevant in addition.This medicine improves plateau the army and the people's health and has opened up another new approach for preventing and treating high altitude erythrocytosis.
Experimental example 2 tea pigments treatment high altitude erythrocytosis 222 routine observation of curative effect
1, data and method:
1.1 the diagnostic criteria of high red disease is based on hematological examination.Hb 〉=200 gram/L, Rbc 〉=6.5 * 10
12/ L, Hct 〉=65Vol% can make a definite diagnosis.Hematological variation and microcirculation disturbance, peripheral blood silt resistance and hemorheology slow blood flow, hypercoagulability, SOD lowers relevant.Tea pigment is to the existing many reports of the influence of nail fold microcirculation, hemorheology, blood fat, SOD.But the influence to hematology Hb, Rbc, Hct is not reported.
1.2 offer medicine on the spot in high altitude localities more than 3000 meters, inspection on the scene guarantees the integrity and the accuracy of high raw data, and its conclusion is reliable.The purpose of research is the survival ability after protection fighting capacity and individuality enter the plateau.So the improvement of clinical symptoms is observed it in detail as a concrete index.In respect of: dizzy, have a headache, breathe hard, uncomfortable in chest, edema, cardiopalmus, arthralgia, poor appetite, nauseating, fidgety, become thin, chest pain, weak, insomnia, xerosis cutis, diarrhoea, blurred vision, tinnitus, auditory dysesthesia, acroanesthesia, menoxenia, lip cyanosis, finger tip are livid purple, conjunctival congestion, fingernail cave in, more than totally 25.
1.3 four medical team are left for different regions.Qinghai red cross hospital sets up an office on the Hao Men farm, (3100 meters-3600 meters of height above sea level), Xining hospital of Railway Bureau sets up an office at the Hai Xihaer lid, (3300 meters of height above sea level), People's Armed Police Qinghai hospital of army unit sets up an office in Golog Da Wu area, (3500 meters-4300 meters of height above sea level), the communication hospital, Qinghai selects case along Qinghai-Tibet Highway in workman of railway maintenance squad and civilian worker.(3000 meters-4500 meters of height above sea level).Four unified standards of taking medicine of group, 125 milligrams, day 3 clothes, 40 days is a course of treatment.The unified regulation of criterion of therapeutical effect.
2, efficacy assessment standard:
2.1 produce effects: Hb≤180 gram/L, Rbc≤5.5 * 10
12/ L, Hct≤55Vol%; Nail fold microcirculation takes a turn for the better one more than the grade, and hemorheology whole blood, plasma viscosity obviously change general; Antisecosis, original symptom improve more than 1/2, can adhere to plateau work.
2.2 effectively: Hb decline less than 20 gram/L, Rbc decline less than 1 * 10
12/ L, the Hct not enough 10Vol% that descends; Nail fold microcirculation, hemorheology obviously improve; Muscle power has recovery, and original symptom is partly improved.Adhere to that the plateau work has certain difficulty.
2.3 invalid: blood test, nail fold microcirculation, hemorheology, clinical shape do not improve, or change the low altitude area therapist midway over to.
3, observed result:
The results are shown in following table:
| Unit | Height above sea level | The example number | Produce effects | Effectively | Invalid | Total effective rate |
| Communication hospital, Xining railway hospital of Qinghai red cross hospital People's Armed Police Qinghai army unit hospital Qinghai adds up to | 3100 meters-3600 meters 3300 meters 3500 meters-4300 meters 3000 meters-4500 meters | 52 90 50 30 222 | 12(23％) 42(46.6％) 22(44％) 13(43％) 89(40％) | 15(28.8％) 28(31.1％) 26(52％) 15(50) 84(37.8％) | 25(48％) 20(22.2％) 2(4％) 2(6.6％) 49(22％) | 52％ 77.8％ 96％ 93.4％ 78％ |
There were significant differences (P＜0.01) that 52 examples are treated by Qinghai red cross hospital for four medical center therapeutic effect, and wherein produce effects 12 examples account for 23%, and effective 15 examples account for 28.8%, and invalid 25 examples account for 48%; Xining railway hospitalize 90 examples, wherein produce effects 42 examples account for 46.6%, and effective 28 examples account for 31.1%, and invalid 20 examples account for 22.2%; People's Armed Police Qinghai army unit hospitalize 50 examples, produce effects 22 examples account for 44%, and effective 26 examples account for 52%, and invalid 2 examples account for 4%, and 30 examples are treated by the communication hospital, Qinghai, and produce effects 13 examples account for 43%, and effective 15 examples account for 50%, and invalid 2 examples account for 6.6%.
The reason that significant difference occurs.The one, the time difference of migrating the plateau is big, and the 2nd, age difference is big.Red cross hospital's treatment target is the farm cadre, and the inhabitation time is many more than 10 years, 51 years old mean age.Armed Police contingent's hospitalize is to liking the officers and men of army, enter the plateau majority within 5 years, 29 years old mean age, Xining railway hospital and communication hospital's treatment target are railway, highway worker, the civilian worker who goes into the plateau when part is seasonality, wherein person between twenty and fifty occupy the majority.This explanation tea pigment is treated high red disease, and medical history is short more, and the age, low more effect was good more, and the red disease effect of chronic height is then weaker.
Tea pigment is treated high red disease certain curative effect, and effective percentage reaches 78%, and clinical observation is similar to Rhodiola kirilowii (Regel) Maxim..Be better than Western medicine diethylstilbestrol (effective percentage is 63.3%).It is one of optional medicine of treatment high altitude erythrocytosis.
Claims (1)
1, the application of tea pigment in the medicine of preparation treatment high altitude erythrocytosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116635A CN1078472C (en) | 1997-08-08 | 1997-08-08 | Application of theachrome in preparing medicine for plateau erythrocytosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116635A CN1078472C (en) | 1997-08-08 | 1997-08-08 | Application of theachrome in preparing medicine for plateau erythrocytosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1207913A CN1207913A (en) | 1999-02-17 |
| CN1078472C true CN1078472C (en) | 2002-01-30 |
Family
ID=5173991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97116635A Expired - Fee Related CN1078472C (en) | 1997-08-08 | 1997-08-08 | Application of theachrome in preparing medicine for plateau erythrocytosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1078472C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101715957B (en) * | 2009-11-18 | 2012-10-24 | 南京中医药大学 | Compound tea pigment with the function of improving hypoxia tolerance, preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081575A (en) * | 1992-12-29 | 1994-02-09 | 武汉市职工医学院 | The extracting method of Tea Pigment |
-
1997
- 1997-08-08 CN CN97116635A patent/CN1078472C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081575A (en) * | 1992-12-29 | 1994-02-09 | 武汉市职工医学院 | The extracting method of Tea Pigment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1207913A (en) | 1999-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101554362A (en) | Composition of natural product and preparation thereof | |
| CN112891362B (en) | Pharmaceutical composition for treating sepsis and application thereof | |
| CN1078472C (en) | Application of theachrome in preparing medicine for plateau erythrocytosis | |
| CN108324816A (en) | A kind of anaesthetic and preparation method thereof for treating rheumatic arthritis | |
| CN101433586B (en) | A kind of medicine for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN104547619B (en) | It is a kind of to be used to treat Chinese medicine of apoplexy sequelae hemiplegia of limb and preparation method thereof | |
| CN1401365A (en) | Chinese health medicine | |
| CN101642486B (en) | Chinese herb composition for promoting wound healing and preparation method thereof | |
| CN1460511A (en) | Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases | |
| CN1192771C (en) | Medicine for treating rheumatism and rheumatoid disease | |
| CN104758578A (en) | Traditional Chinese medicine composition for treating palpitation | |
| CN1066339C (en) | Application of theaflavine for prepn. of medicine for treating deafness | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN1064254C (en) | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| Igbokwe et al. | Aqueous extracts of Vernonia amygdalina and Ocimum gratissimum protect against electrolyte derangement in salt-loaded rats | |
| CN1289609A (en) | Chinese patent medicine (Tangweiping) for treating eyeground affection of diabetes | |
| CN1057005C (en) | Application of theaflavine for preparing medicine for treating leukopenia disease | |
| CN102008520A (en) | Drug for preventing and treating chronic mountain sickness and preparation method thereof | |
| CN101229227B (en) | Water aqua medicine compounds, preparing method and applications thereof | |
| CN105194317A (en) | Traditional Chinese medicine composition for treating bone joint injuries and application of traditional Chinese medicine composition | |
| CN105412357A (en) | Drug combination capable of preventing radiation cataract | |
| CN1057004C (en) | Application of theaflavine for preparing medicine for treating cerebral infarction | |
| CN1057000C (en) | Application of tea pigments in preparation of medicine for fatty liver | |
| CN103751494A (en) | Traditional Chinese medicine composition for treating pertussis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |